亿帆医药：关于2025年前三季度计提资产减值准备的公告

Core Viewpoint - Yifan Pharmaceutical announced a comprehensive review of its financial status and asset values, leading to the recognition of asset impairment for the period ending September 30, 2025, with a total impairment provision of 44.31 million yuan for the first nine months of 2025 [2] Financial Assessment - The company conducted a thorough assessment of its consolidated financial statements to identify any signs of asset impairment [2] - The impairment provision of 44.31 million yuan was recorded for the period from January to September 2025 [2]